Clinician reference tool — not medical advice. This is a clinical decision-aid intended for healthcare professionals: it gives deterministic suggestions to think with, not a diagnosis or a prescription. If you’re a patient, you’re welcome to look around — but please review anything here with your own doctor; it isn’t a substitute for personalized medical care.

Evidence: CADDRA — Canadian ADHD Practice Guidelines, 4.1 edition (… 2026 · sources last checked 2026-08-20

Reference tool — not medical advice. Thresholds, targets, and first-line agents differ by guideline body and change over time — switch the lens to compare. Clinician judgement, dosing/monitoring, contraindications, and live coverage always required. Runs entirely in your browser — no data is collected.

Adult ADHD selector

Choose the guideline lens (CADDRA / NICE), enter comorbidities and risk factors — get the plan: long-acting stimulants first-line, with routing to a non-stimulant (atomoxetine) when substance-use or diversion risk is present, baseline cardiac screening, and comorbidity-specific cautions. (Assumes a confirmed adult ADHD diagnosis.)

Guideline lens

Comorbidities

Misuse / diversion riskchoose one

Environmental / non-pharmacologic measureschoose one

Prior response

Special

First-line

Long-acting stimulant (methylphenidate or amphetamine)

Notes

  • • CADDRA: long-acting stimulants are first-line (stimulants are the treatment of choice when urgent); guanfacine XR is an 'other option' for adults; bupropion is off-label third-line. All stimulants are controlled substances (secure/triplicate prescriptions).

Suggested drug classesPer CADDRA (Canada) 2026.

Select comorbidities and misuse risk to begin.

Switch the lens to see the difference: NICE gates medication behind environmental modifications and does not offer guanfacine to adults; CADDRA leads with long-acting stimulants.

Guidelines

References

  1. [1]CADDRA — Canadian ADHD Practice Guidelines, 4.1 edition (2021) and Guide to ADHD Pharmacological Treatments in Canada (medication chart, 2026). Long-acting stimulants first-line; abuse-potential tiering; controlled-substance prescribing. link
  2. [2]NICE NG87 — Attention deficit hyperactivity disorder: diagnosis and management (2019). Medication after environmental modifications; lisdexamfetamine/methylphenidate first, 6-week switch, then atomoxetine; do not offer guanfacine to adults. link